References
- Faden J, Citrome L. Schizophrenia: one name, many different manifestations. Med Clin North Am. 2023;107(1):61–72.
- John M. Eisenberg Center for clinical decisions and communications science. Off-Label use of atypical antipsychotics: an update. 2012 Aug 1. In: Comparative Effectiveness review summary guides for clinicians [internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2007.
- Tremeau F, Citrome L. Antipsychotics for patients without psychosis? What clinical trials support. Current Psychiatry. 2006;5(12):33–44. https://www.mdedge.com/psychiatry/article/62455/antipsychotics-patients-without-psychosis
- López-Muñoz F, Alamo C, Cuenca E, et al. History of the discovery and clinical introduction of chlorpromazine. Ann Clin Psychiatry. 2005;17(3):113–135.
- Granger B, Albu S. The haloperidol story. Ann Clin Psychiatry. 2005;17(3):137–140.
- López-Muñoz F, Alamo C. The consolidation of neuroleptic therapy: janssen, the discovery of haloperidol and its introduction into clinical practice. Brain Res Bull. 2009;79(2):130–141. Epub 2009 Jan 30.
- Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. Hist Psychiatry. 2007;18(1):39–60.
- Citrome L, Nasrallah HA. On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not. Expert Opin Pharmacother. 2012;13(11):1599–1613.
- McCutcheon RA, Abi-Dargham A, Howes OD. Schizophrenia, dopamine and the striatum: from biology to symptoms. Trends Neurosci. 2019;42(3):205–220.
- Correll CU, Abi-Dargham A, Howes O. Emerging Treatments in schizophrenia. J Clin Psychiatry. 2022;83(1):SU21204IP1.
- Hopkins SC, Lew R, Zeni C, et al. Challenges in the clinical development of non-D2 compounds for schizophrenia. Curr Med Res Opin. 2022. DOI:10.1080/03007995.2022.2147342
- Kane JM. A New treatment paradigm: targeting trace Amine-Associated receptor 1 (TAAR1) in schizophrenia. J Clin Psychopharmacol. 2022;42(5 Suppl 1):S1–S13.
- Halff EF, Rutigliano G, Garcia-Hidalgo A, et al. Trace amine-associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disorders. Trends Neurosci. 2022;S0166-2236(22):00211–00219.
- Berlant JL. Neuroleptics and reserpine in refractory psychoses. J Clin Psychopharmacol. 1986;6(3):180–184.
- Jankovic J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother. 2016;17(18):2461–2470.
- Christison GW, Kirch DG, Wyatt RJ. When symptoms persist: choosing among alternative somatic treatments for schizophrenia. Schizophr Bull. 1991;17(2):217–245.
- Koblan KS, Kent J, Hopkins SC, et al. A Non-D2-Receptor-Binding drug for the treatment of schizophrenia. N Engl J Med. 2020;382(16):1497–1506.
- Pahwa M, Sleem A, Elsayed OH, et al. New Antipsychotic medications in the last decade. Curr Psychiatry Rep. 2021;23(12):87.
- Bender AM, Jones CK, Lindsley CW. Classics in chemical neuroscience: xanomeline. ACS Chem Neurosci. 2017;8(3):435–443.
- Yohn SE, Weiden PJ, Felder CC, et al. Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic. Trends Pharmacol Sci. 2022;43(12):1098–1112.
- Pfeiffer CC, Jenney EH. The inhibition of the conditioned response and the counteraction of schizophrenia by muscarinic stimulation of the brain. Ann N Y Acad Sci. 1957;66(3):753–764.
- Brannan SK, Sawchak S, Miller AC, et al. Muscarinic Cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med. 2021;384(8):717–726.
- Correll CU, Angelov AS, Brannan SK. Safety and Efficacy of KarXT (Xanomeline–Trospium) in Patients with Schizophrenia: results from a Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial (EMERGENT-2). Poster presentation P.0193, 35th ECNP Congress, 15-18 October 2022, Vienna, Austria.